Global Juvenile Macular Degeneration (Stargardt Disease) Market: Information by Diagnosis (Fluorescein Angiography and others), Management (Magnifying Spectacles and others), End User (Hospital & Eye Clinics and others) and Region - Forecast till 2027
ID: MRFR/Pharma/3504-CR | July 2019 | Region: Global | 119 pages
Market Overview
The Global Juvenile Macular Degeneration (Stargardt Disease) Market is expected to register a CAGR of 6.7% and is anticipated to reach USD 1593.885 million by 2027.
Juvenile macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, juvenile macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for sharp central vision, which is needed for detailed tasks such as reading, driving, and recognizing faces. The market is mainly driven by factors such as the increasing prevalence of eye disorders, development of new drugs and therapies, and emerging government policies. However, the high cost of treatment and lack of reimbursement is expected to restrain the growth of this market.
Market Dynamics
The rising prevalence of eye disorder and technological advancements in juvenile macular degeneration are some of the factors that drive the growth of the market. Juvenile macular degeneration is a rare inherited eye condition which affects the central area of the retina called the macula, also known as fundus flavimaculatus. It affects about 1 in 10,000 people and is sometimes called juvenile macular dystrophy since it tends to first appear between the ages of 10 to 20 although visual impairment may not be apparent until as late as ages 30 to 40. Juvenile macular degeneration disease causes parts of the macula to stop working, leading to problems with central vision, detailed vision, and sometimes with color perception. The major driving factors for the global juvenile macular degeneration market are increasing the prevalence of eye disorders, development of new drugs, and therapies, and emerging government policies. However, lack of awareness and no treatment option for juvenile macular dystrophy may hamper the market growth.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Size, by Diagnosis, 2016 and 2027 (USD Million) 
Source: MRFR Analysis
Segmentation
The global juvenile macular degeneration (Stargardt disease) market has been segmented into diagnosis, management, and end user. Based on the diagnosis, the market has been segregated into fluorescein angiography (FA), fundus autofluorescence (FAF), optical coherence tomography (OCT), and electroretinography (ERG). The FA segment accounted for a market value of USD 270.110 million in 2016. Based on management, the market has been segregated into magnifying spectacles, magnifiers, and reading telescopes. The global juvenile macular degeneration (Stargardt disease) market on the basis of end-user is divided into hospital & eye clinics, and research & academic institutes.
Key Players
The prominent players in the global juvenile macular degeneration (Stargardt disease) market are Astellas Pharma Inc (Japan), Sanofi (France), Acucela Inc (Japan), Alkeus Pharma (US), Copernicus Therapeutics (US), Ophthotech Corporation (US), Bayer AG (Germany), Oxford BioMedica PLC (UK), and Grupo Ferrer (Spain).
Some of the key strategies followed by the players operating in the global juvenile macular degeneration (Stargardt disease) market were innovation, product development, acquisition, mergers, and expansion.
Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, by Region, 2016 (%) 
Source: MRFR Analysis
Regional Analysis
The global juvenile macular degeneration (Stargardt disease) market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Europe accounted for the significant share in the market for juvenile macular degeneration. Rising investment in research & development, well-developed healthcare infrastructure, and increasing healthcare funds are some of the factors responsible for boosting the growth of the market in this region. Europe held the most significant market share of 32.7 % in 2016.
Americas is estimated to be the second-largest market. This is attributed due to the well-developed technology, rising healthcare expenditure, and the presence of the leading players in the market.
Asia-Pacific is projected to be the fastest-growing market due to the rising aging population, increasing healthcare expenditure, and rapidly changing healthcare sector. In addition to this, improving healthcare facilities and rising economic growth is positively impacting the market growth in this region.
The market in the Middle East & Africa is expected to witness steady growth due to increasing investments in research & development, well-developed infrastructure, and advancement in technology.
Key Updates
- In November 2017, Astellas Pharma Inc launched “Repatha” a human monoclonal antibody for the treatment of hypercholesterolemia.
- In December 2017, Sanofi acquired Protein Science company in order to expand its product portfolio.
- In January 2017, Acucela Inc received orphan drug approval for treatment of Stargardt disease. Hence this product approval will help the company to increase its revenue in the future as very few drugs are available for the treatment of Stargardt disease.
Market Segmentation
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Diagnosis
- Fluorescein Angiography (FA)
- Fundus Autofluorescence (FAF)
- Optical Coherence Tomography (OCT)
- Electroretinography (ERG)
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Management
- Magnifying Spectacles
- Magnifiers
- Reading telescopes
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by End-User
- Hospital & Eye Clinics
- Research & Academic Institutes
Global Juvenile Macular Degeneration (Stargardt Disease) Market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- North America
- Europe
- Western Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Western Europe
- Eastern Europe
- Western Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Available Additional Customizations
Intended Audience
- Medical device manufacturers and distributors
- Government research organizations
- Hospitals and clinics
- Regulatory agencies
- Contract research organizations
- Pharmaceutical companies
- Medical research laboratories
Frequently Asked Questions (FAQ) :
juvenile macular degeneration (stargardt disease) market projected to grow at approximately 6.7% CAGR during the assessment period (2018-2027).
How much is the global juvenile macular degeneration (stargardt disease) market worth in the future?
The valuation of the global juvenile macular degeneration (stargardt disease) market is estimated to increase to USD 1593.885 MN by the end of 2027.
Increasing prevalence of eye disorder and technological advancements in juvenile macular degeneration are major tailwinds pushing the growth of the global juvenile macular degeneration (stargardt disease) market.
North America holds the largest share in the global juvenile macular degeneration (stargardt disease) market, followed by Europe and the Asia Pacific, respectively.
Alkeus Pharmaceuticals Inc. (U.S.), Acucela Inc. (U.S.), Astellas Pharma Inc. (Japan), Sanofi (France), ProQR Therapeutics NV (Netherland), Bayer HealthCare (Germany), Copernicus Therapeutics Inc. (U.S.), F. Hoffmann-La Roche (Switzerland), Grupo Ferrer Internacional SA (U.S.), Nemus Bioscience Inc. (U.S.), Iris Pharma (U.S.), Ophthotech Corp (U.S.), Adverum Biotechnologies (U.S.), Iconic Therapeutics (U.S.), PanOptica (U.S.), Neurotech Pharmaceuticals (U.S.), and RXi Pharmaceuticals (U.S.), are some of the top players operating in the global juvenile macular degeneration (stargardt disease) market.
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3 Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5 Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6 Global Juvenile Macular Degeneration (Stargardt Disease) Market, By Diagnosis
6.1 Introduction
6.2 Fluroscein Angiography (FA)
6.2.1 Market Estimates & Forecast, 2020 – 2027
6.3 Fundus Autofluorescence (FAF)
6.3.1 Market Estimates & Forecast, 2020 – 2027
6.4 Optical Coherence Tomography (OCT)
6.4.1 Market Estimates & Forecast, 2020 – 2027
6.5 Electroretinography
6.5.1 Market Estimates & Forecast, 2020 – 2027
7 Global Juvenile Macular Degeneration (Stargardt Disease) Market, By Devices
7.1 Introduction
7.2 Magnifying Spectacles
7.2.1 Market Estimates & Forecast, 2020 – 2027
7.3 Magnifiers
7.3.1 Market Estimates & Forecast, 2020 – 2027
7.4 Reading Telescopes
7.4.1 Market Estimates & Forecast, 2020 – 2027
8 Global Juvenile Macular Degeneration (Stargardt Disease) Market, By End Users
8.1 Introduction
8.2 Hospitals & Eye Clinics
8.2.1 Market Estimates & Forecast, 2020 – 2027
8.3 Research & Academic Institutes
8.3.1 Market Estimates & Forecast, 2020 – 2027
9 Global Juvenile Macular Degeneration (Stargardt Disease) Market, By Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.1 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest Of Western Europe
9.3.2 Eastern Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic Of Korea
9.4.6 Rest Of Asia Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest Of The Middle East & Africa
10 Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
11 Company Profiles
11.1 Alkeus Pharmaceuticals Inc.
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Astellas Pharma Inc
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Allergan PLC
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Pfizer
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 PfBausch + Lomb
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial Overview
11.5.4 Key Developments
11.6 Gilead Sciences Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Gilead Sciences Inc.
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financial
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs Of The Market
12.2 Key Companies To Watch
12.3 Prediction Of Medical End Users Industry
13 Appendix
14 List Of Tables
Table 1 Juvenile Macular Degeneration (Stargardt Disease) Industry Synopsis, 2020 – 2027
Table 2 Global Juvenile Macular Degeneration (Stargardt Disease) Market Estimates And Forecast, 2020 – 2027, (USD Million)
Table 3 Global Juvenile Macular Degeneration (Stargardt Disease) Market By Region, 2020 – 2027, (USD Million)
Table 4 Global Juvenile Macular Degeneration (Stargardt Disease) Market By Diagnosis, 2020 – 2027, (USD Million)
Table 5 Global Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 6 Global Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 7 North America Juvenile Macular Degeneration (Stargardt Disease) Market By Diagnosis, 2020 – 2027, (USD Million)
Table 8 North America Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 9 North America Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 10 US Market By Diagnosis, 2020 – 2027, (USD Million)
Table 11 US Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 12 US Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 13 Canada Market By Diagnosis, 2020 – 2027, (USD Million)
Table 14 Canada Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 15 Canada Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 16 South America Market By Diagnosis, 2020 – 2027, (USD Million)
Table 17 South America Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 18 South America Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 19 Europe Market By Diagnosis, 2020 – 2027, (USD Million)
Table 20 Europe Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 21 Europe Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 22 Western Europe Market By Diagnosis, 2020 – 2027, (USD Million)
Table 23 Western Europe Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 24 Western Europe Juvenile Macular Degeneration (Stargardt Disease) Market By End Userss, 2020 – 2027, (USD Million)
Table 25 Eastern Europe Market By Diagnosis, 2020 – 2027, (USD Million)
Table 26 Eastern Europe Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 27 Eastern Europe Juvenile Macular Degeneration (Stargardt Disease) Market By End Userss, 2020 – 2027, (USD Million)
Table 28 Asia Pacific Market By Diagnosis, 2020 – 2027, (USD Million)
Table 29 Asia Pacific Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 30 Asia Pacific Juvenile Macular Degeneration (Stargardt Disease) Market By End Users, 2020 – 2027, (USD Million)
Table 31 Middle East & Africa Market By Diagnosis, 2020 – 2027, (USD Million)
Table 32 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Market By Devices, 2020 – 2027, (USD Million)
Table 33 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Market By End Userss, 2020 – 2027, (USD Million)
15 List Of Figures
Figure 1 Research Process
Figure 2 Segmentation For Global Juvenile Macular Degeneration (Stargardt Disease) Market
Figure 3 Segmentation Market Dynamics For Global Juvenile Macular Degeneration (Stargardt Disease) Market
Figure 4 Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Type 2020
Figure 5 Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Devices 2020
Figure 6 Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, By End Userss, 2020
Figure 7 Global Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Region, 2020
Figure 8 North America Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Country, 2020
Figure 9 Europe Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Country, 2020
Figure 10 Asia Pacific Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Country, 2020
Figure 11 Middle East & Africa Juvenile Macular Degeneration (Stargardt Disease) Market Share, By Country, 2020
Figure 12 Global Juvenile Macular Degeneration (Stargardt Disease) Market: Company Share Analysis, 2020 (%)
Figure 13 Merck: Key Financials
Figure 14 Merck: Segmental Revenue
Figure 15 Merck: Geographical Revenue
Figure 16 Astellas Pharma Inc. Key Financials
Figure 17 Astellas Pharma Inc. Segmental Revenue
Figure 18 Astellas Pharma Inc. Geographical Revenue
Figure 19 Bayer: Key Financials
Figure 20 Bayer: Segmental Revenue
Figure 21 Bayer: Geographical Revenue
Figure 22 Pfizer: Key Financials
Figure 23 Pfizer: Segmental Revenue
Figure 24 Pfizer: Geographical Revenue
Figure 25 Bausch + Lomb: Key Financials
Figure 26 Bausch + Lomb: Segmental Revenue
Figure 27 Bausch + Lomb: Geographical Revenue
Figure 28 Gilead Sciences Inc.: Key Financials
Figure 29 Gilead Sciences Inc.: Segmental Revenue
Figure 30 Gilead Sciences Inc.: Geographical Revenue
Figure 31 Gilead Sciences Inc.: Key Financials
